Showing 49–60 of 213 resultsSorted by latest
Pharma & Biotech
Oncology remains JNJ’s strongest growth catalyst, achieving 22.3% operational growth in Q2FY25..
Abbott’s Q2FY25 performance was broad-based, with Medical Devices delivering 12.2% organic growth and EPD delivering stable growth of 7.7%.
Veeva’s results for Q1FY25 demonstrated impeccable operational performance, greatly exceeding forecasts for both revenue and profitability
The Ignite transformation initiative is a key factor in Agilent’s strength, expected to generate more than $130mn in earnings for FY25.
ASCENIV is scaling fast, backed by a stronger supply chain and growing market position.
Zoetis’s Q1FY25 performance demonstrates a robust underlying business, evidenced by a strong 9% organic operational revenue growth, despite reported revenue increasing by only 1%.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Revenues of Gilead in Q1FY25 remained flat at $6.67bn compared to last year same period, but has showed a comeback in terms of profitability.
Cigna Group has reported strong earnings in Q1FY25 across all segments, especially its core segments, Cigna Healthcare and Evernorth Health Services, revenues touching $65.6bn,a significant increase of 14% from the same period last year.
Orenitram, revenues touched $120.7mn in Q1FY25, representing a growth of 13.7% from $106.2mn in Q1FY24 and Remodulin, contributed a 8% increase in revenues from $128mn in Q1FY24 to $138.2mn in Q1FY25, this shows that the overall portfolio of UTHR has a solid balance across its product line.
Regeneron’s primary growth driver for future growth has to be it’s investments in strong R&D. Regeneron plans to invest $5bn into R&D in 2025.
Edward Lifesciences has reported a strong Q1 revenue growth with sales touching $1.41bn which is a 6.2% increase compared to previous year of the same period.